Treatment-resistant depression accounts for about 17 percent of depressed individuals in the U.S. To be diagnosed with treatment-resistant depression, a person must have not experienced an adequate decrease in depressive symptoms after at least four medication regimens.
Abbott’s deep brain stimulation uses wires — or leads — in certain areas of the brain to send electrical impulses that can affect brain activity.
The company’s Infinity DBS System was approved as a treatment for Parkinson’s disease and tremors and has now been given the FDA breakthrough device designation for use on patients with treatment-resistant depression, according to Abbott.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
